X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse VENUS REMEDIES with TEVA PHARMACEUTICAL INDUSTRIES LTD. - Israel - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs TEVA PHARMA (Israel) - Comparison Results

TEVA PHARMA (Israel)
   Change

Teva Pharmaceuticals, established in 1901, is a global pharmaceutical company. The company is into development, production and marketing of a wide range of specialty medicines, generic and OTC products, active pharmaceutical ingredients (API) and nov... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 VENUS REMEDIES   TEVA PHARMA
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-16
TEVA PHARMA
Dec-13
VENUS REMEDIES/
TEVA PHARMA
5-Yr Chart
Click to enlarge
High Rs2182,709-   
Low Rs822,353-   
Sales per share (Unadj.) Rs365.61,554.5-  
Earnings per share (Unadj.) Rs1.597.1-  
Cash flow per share (Unadj.) Rs37.9222.8-  
Dividends per share (Unadj.) Rs085.01-  
Dividend yield (eoy) %03.4 0.0%  
Book value per share (Unadj.) Rs382.51,726.7-  
Shares outstanding (eoy) m11.44848.00-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.41.6 25.2%   
Avg P/E ratio x101.026.1 387.4%  
P/CF ratio (eoy) x4.011.4 34.8%  
Price / Book Value ratio x0.41.5 26.8%  
Dividend payout %087.5 0.0%   
Avg Mkt Cap Rs m1,7172,146,042 0.1%   
No. of employees `0001.044.9 2.3%   
Total wages/salary Rs m3240-   
Avg. sales/employee Rs Th4,100.729,328.6 14.0%   
Avg. wages/employee Rs Th318.00-   
Avg. net profit/employee Rs Th16.71,832.1 0.9%   
INCOME DATA
Net Sales Rs m4,1831,318,175 0.3%  
Other income Rs m200-   
Total revenues Rs m4,2031,318,175 0.3%   
Gross profit Rs m812360,983 0.2%  
Depreciation Rs m417106,549 0.4%   
Interest Rs m38025,891 1.5%   
Profit before tax Rs m35228,543 0.0%   
Minority Interest Rs m01,038 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-150,026 0.0%   
Tax Rs m18-2,790 -0.6%   
Profit after tax Rs m1782,345 0.0%  
Gross profit margin %19.427.4 70.9%  
Effective tax rate %51.6-1.2 -4,223.7%   
Net profit margin %0.46.2 6.5%  
BALANCE SHEET DATA
Current assets Rs m2,771890,291 0.3%   
Current liabilities Rs m1,931776,409 0.2%   
Net working cap to sales %20.18.6 232.3%  
Current ratio x1.41.1 125.1%  
Inventory Days Days12591 137.7%  
Debtors Days Days5496 56.0%  
Net fixed assets Rs m5,328430,545 1.2%   
Share capital Rs m1143,245 3.5%   
"Free" reserves Rs m4,1770-   
Net worth Rs m4,3761,464,243 0.3%   
Long term debt Rs m1,911674,012 0.3%   
Total assets Rs m8,4283,012,453 0.3%  
Interest coverage x1.19.8 11.1%   
Debt to equity ratio x0.40.5 94.8%  
Sales to assets ratio x0.50.4 113.4%   
Return on assets %4.73.6 131.0%  
Return on equity %0.45.6 6.9%  
Return on capital %6.64.9 133.8%  
Exports to sales %00-   
Imports to sales %20.50-   
Net fx Rs m-8580-   
CASH FLOW
From Operations Rs m469210,049 0.2%  
From Investments Rs m29-74,429 -0.0%  
From Financial Activity Rs m-464-251,968 0.2%  
Net Cashflow Rs m35-116,348 -0.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for TEVA PHARMA (Israel) is United States Dollars. All data has been converted at 64.89 Rs / USD

Compare VENUS REMEDIES With: MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  

Compare VENUS REMEDIES With: ELDER PHARMA  ALEMBIC PHARMA  UNICHEM LAB  CIPLA  GSK PHARMA  



Today's Market

Strong Finish to the Week; Metal & Pharma Stocks Gain(Closing)

Indian share markets finished the trading session on a strong note amid firm Asian markets after comments from a Federal Reserve official eased worries about faster rate hikes in US.

Related Views On News

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


Feb 23, 2018 (Close)

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES - AJANTA PHARMA COMPARISON

COMPARE VENUS REMEDIES WITH

MARKET STATS